Clinical Trials Directory
In this study, all participants will receive a study medicine called xaluritamig through a tube placed in a vein. Each treatment takes about one hour. At the start, lower doses are given every two weeks. Later, treatments are given every four weeks. Before starting, you will have tests such as blood work, scans, and a physical exam to make sure you can join the study. During the study, you will have regular clinic visits for treatments, checkups, blood tests, and scans like CT or MRI to watch your health and your cancer. Early in treatment, you may need to stay at the clinic or hospital for a short time after the medicine is given so doctors can monitor you. You will also need a caregiver to help you for a short time after treatment. You can keep receiving the medicine as long as it is helping you, and doctors will continue to check on you for up to about two years.
In this study, people will be placed into one of two groups by chance. One group will receive two medicines, called romiplostim and prednisone. The other group will receive only prednisone, which is the usual treatment. During the first part of the study, people in the study treatment group will receive weekly shots of romiplostim for up to 24 weeks and take prednisone for up to 8 weeks. People in the usual treatment group will take prednisone for up to 8 weeks. After 24 weeks, everyone will move to the second part of the study. The study treatment group may continue receiving romiplostim for up to one year, while the usual treatment group will not receive the study medicine. Throughout the study, participants will visit the clinic for blood tests and physical exams so doctors can check their health and see how well the treatment is working.
We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.
We are doing this study to learn more about how androgens, a type of sex hormone, might affect women who have nonalcoholic fatty liver disease (NAFLD). We want to see if they play a role in how the disease effects women over time, and we also want to see what role these hormones might play in the relationship between NAFLD and polycystic ovary syndrome.
We are doing this study to find the most effective, safe dose of a combination of the drugs fianlimab and ceminplimab. We want to know if this combination is an option for people with melanoma. We will compare how well this drug combination works to the usual treatment of relatlimab and nivolumab, which has the brand name Opdualag®.